Current Hematologic Malignancy Reports
Impact Factor Trend (2018–2026)
Clarivate IF trend for Current Hematologic Malignancy Reports
SCImago Journal Rank citation prestige weighting
52 papers with at least that number of citations each
Aims & Scope
his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
Special Issues
Calls for PapersNo active Calls for Papers found for this journal.
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
HEMATOLOGY
ONCOLOGY
HEMATOLOGY
ONCOLOGY
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Journal Metrics & Citation Visualizations
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Academic Intelligence Overview & Context
ImpaQ AnalysisCurrent Hematologic Malignancy Reports (acronym: chmr, abbr: CURR HEMATOL MALIG R, ISSN: 1558-8211) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by Springer US in United States since 2006. The periodical holds a Journal Impact Factor (JIF) of 4.00, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.191 (Q1), an H-index of 52.
The journal enforces rigorous peer evaluation with a publication frequency of 6 issues per year, an annual output of approximately 55 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,371 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics